Introduction
Langerhans cell histiocytosis (LCH) is a rare benign histiocytoic disorder most commonly characterized by single or multiple osteolytic bone lesions but also ulcerations of skin and soft tissues and also involvement of the CNS are described. It is characterized by an uncontrolled clonal proliferation of langerhans cells which belong to the normal human mononuclear phagocytic system. Langerhans cell histiocytosis (LCH) formerly referred to as histiocytosis X, can be divided into three categories: eoisnophilic granuloma, Hand Schuller Christian disease and Abt_Letterer-Siwe disease. LCH involves single (single-system disease) or multiple (multiple-System disease) organ systems. In 60% bony manifestations as single-system disease with uni or multifocal lesions are present but also in multi-system disease with activity in other organ systems are also described. In case of involvement of the CNS diabetes insipidus is a typical symptom. Patients with single system disease tend do well. Patients with multiple system disease sometimes have an unpredictable outcome. Patients with only one bony lesion progression, disseminated disease and fatal outcome has been described. Nevertheless some self healing and self limiting courses has been reported.
II. Material Methods
We are presenting such rare disease of Langerhans histiocytosis who attended our OPD at Regional cancer Centre Raipur Chhattisgarh. Our study includes four patients with isolated and those with multifocal bone lesion treated with chemotherapy and Radiotherapy. The aim of our study is to find out disease free survival, recurrent disease death and therapy related side effects of chemotherapy & Radiotherapy. According to the LCH classification of Greenberger et al two child were having stage III disease & two adult having stage II disease. 
III. Results And Discussion
In accordance with the nature of LCH all three patient were having NAD (Non Active disease) with regressive disease having regression of sign and symptoms with no new lesions. The patients are advised for 12month pulse therapy of maintenance and thereafter advised for the follow up investigation after and therapy. For clinical exam every 6weeks for 1 year then every 3monts for one year and 6monthly for next 2years. Similarly height, weight and pubertal status every 6month for 5years. Patients were kept on follow up with Radiographs of some lesion only if new lesion or reactivations are suspected.
IV. Conclusions
Due to rarity of LCH and the variety of symptoms of the disease, oncologist encounters a number of diagnostic and therapeutic difficulties Chemotherapy and Radiotherapy is a safe and effective treatment option for patient suffering from LCH Chemotherapy for the multifocal lesion. Low RT dose to unifocal lesion shows sufficient local control. Side effect are low and no treatment related deaths were observed.
